Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8802690 | 0.79 | DRD1 (0.54) | DRD1NOS1AXLIDO1 | |
| SCHEMBL31509830 | 0.75 | NOS1 (0.52) | DRD1NOS1AXLIDO1TDO2 | |
| SCHEMBL26116145 | 0.75 | NOS1 (0.52) | DRD1NOS1AXLIDO1TDO2 | |
| SCHEMBL382320 | 0.75 | NOS1 (0.52) | DRD1NOS1AXLIDO1METAP2 | |
| SCHEMBL29366567 | 0.75 | NOS1 (0.52) | DRD1NOS1AXLIDO1METAP2 | |
| SCHEMBL1155424 | 0.75 | NOS1 (0.42) | DRD1NOS1AXLIDO1METAP2 | |
| SCHEMBL25175308 | 0.72 | PIK3CA (0.43) | DRD1NOS1NOS3NOS2IDO1 | |
| SCHEMBL29799637 | 0.72 | PI4KA (0.55) | RETPI4KAXDHLRRK2PI4K2B | |
| SCHEMBL19664493 | 0.72 | CCNA2 (0.49) | DRD1NOS1AXLRAF1BRAF | |
| SCHEMBL12321248 | 0.71 | NOS1 (0.56) | NOS1AXLIDO1TDO2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013139882-A1 | PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | WO | claimed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250154150-A1 | SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | SUZHOU YABAO PHARMACEUTICAL R & D CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| EP-4484427-A1 | SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Suzhou Yabao Pharmaceutical R&D Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-119072478-A | Substituted fused ring compounds, pharmaceutical compositions, preparation method and use thereof | 苏州亚宝药物研发有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| US-20060094682-A1 | Kinase inhibitors for the treatment of diabetes and obesity | ODYSSEY THERA, INC. (US) | 2006-05-04 | — | — | US | disclosed |
| EP-1469810-A2 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-BETA PEPTIDE-RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040028673-A1 | Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders | ROCKEFELLER UNIVERSITY, THE | 2004-02-12 | — | — | US | disclosed |
| US-20030199002-A1 | Clk-2 nucleic acids, polypeptides and uses thereof | MMV FINANCIAL INC. (CA) | 2003-10-23 | — | — | US | disclosed |
| WO-2003057165-A2 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2003-07-17 | — | — | WO | disclosed |
| US-5593997-A | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors | PFIZER INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5593997-A | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors | PFIZER INC. (US) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | RET 1032/4885PI4KA 162/4885XDH 212/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | RET 1795/4885PI4KA 1073/4885XDH 223/4885 |
| US-20040028673-A1 | Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders | BACE1, APP, BACE2 | RET 4279/4885PI4KA 1957/4885XDH 2293/4885 |
| US-20250154150-A1 | SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | LRRK2, WEE2, WEE1 | RET 619/4885PI4KA 493/4885XDH 2629/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | RET 1406/4885PI4KA 847/4885XDH 574/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | RET 686/4885PI4KA 80/4885XDH 364/4885 |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | RET 476/4885PI4KA 237/4885XDH 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.